HOOI的个人主页 - 老虎社区

HOOI

暂无个人介绍

IP属地：未知

6关注

0粉丝

0主题

0勋章

2021-12-29

Wait

Cathie Wood's prediction for a 20% gain in 2021 sours as Ark's flagship fund sees worst return since inception

2021-11-12

Like

The Smartest Stocks to Buy With $20 Right Now

2021-10-06

Good post

Palantir selected by U.S. Army for intelligence data fabric, analytics solution

2021-08-19

Oh..

Some China concepts stocks tumbled in morning trading

2021-08-13

Oh no

抱歉，原内容已删除

2021-08-13

Great performance

Disney jumps over 5% as financials, subscribers top Street expectations

2021-08-12

Overvalue

BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3576901678834606,"uuid":"3576901678834606","gmtCreate":1613812112370,"gmtModify":1613812112370,"name":"HOOI","pinyin":"hooi","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":6,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-1","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识体验官","description":"观看学堂课程满5节","bigImgUrl":"https://static.tigerbbs.com/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://static.tigerbbs.com/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":692097390,"gmtCreate":1640789044505,"gmtModify":1640789044505,"author":{"id":"3576901678834606","authorId":"3576901678834606","authorIdStr":"3576901678834606","name":"HOOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576901678834606"},"themes":[],"htmlText":"Wait","listText":"Wait","text":"Wait","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692097390","repostId":"1121988660","repostType":4,"repost":{"id":"1121988660","pubTimestamp":1640750325,"share":"https://www.laohu8.com/m/news/1121988660?lang=&edition=full","pubTime":"2021-12-29 11:58","market":"us","language":"en","title":"Cathie Wood's prediction for a 20% gain in 2021 sours as Ark's flagship fund sees worst return since inception","url":"https://stock-news.laohu8.com/highlight/detail?id=1121988660","media":"Businessinsider","summary":"Cathie Wood's expectation for a 20% gain in her Ark Invest flagship fund didn't pan out this year.\nA","content":"<ul>\n <li>Cathie Wood's expectation for a 20% gain in her Ark Invest flagship fund didn't pan out this year.</li>\n <li>Ark Invest's Disruptive Innovation ETF instead has fallen more than 20% in 2021, representing its worst return since inception.</li>\n <li>Wood now expects the growth-oriented ETF to deliver a compounded annual growth rate of up to 40% over the next 5 years.</li>\n</ul>\n<hr>\n<p>It's been a difficult year for investors in Ark Invest's flagshipDisruptive Innovation ETF, with the fund on track for its worst year of performance since launching in 2014.</p>\n<p>That's after the ETF delivered sky-high returns of 150% in 2020, helping Ark Invest amass more than $17 billion in assets under management in its flagship fund. The ETF is down 21% in 2021, while theS&amp;P 500is up about 30% year-to-date.</p>\n<p>Ark Invest's poor returns in 2021 were likely a surprise to Cathie Wood, who forecasted a five-year compounded annual growth rateof 20% in December of 2020.She now expects even higher returns looking forward, with a recent blog post outlining her view that the fund could deliver a&nbsp;five-year compounded annual growth rate of up to 40%.</p>\n<p>But Wood's prediction for a 20% gain in 2021 looked to be correct earlier this year, with the fund up 25% at its peak in February. Since then, a downturn in work-from-home stocks and unprofitable technology names dragged down its performance considerably.</p>\n<p>The stocks&nbsp;that hit Ark Invest's performance the mostincludeTeladocandZoom Video, which are both down about 50% this year and lowered the fund by 550 and 386 basis points, respectively, according to data fromKoyfin.</p>\n<p>Those losses far outweighed Ark Invest's top performing holding,Tesla, which is up more than 56% year-to-date and boosted the fund by 286 basis points.</p>\n<p>And it's not just Ark Invest's flagship ETF that has had a rough year, with five out of Ark's six active ETF's delivering negative returns year-to-date. The&nbsp;Ark Genomic Revolution ETFis the worst performing fund, down about 33% year-to-date, while the&nbsp;Ark Autonomous Technology and Robotics ETF&nbsp;is the best performing fund, up about 3%.</p>","source":"lsy1636471102575","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood's prediction for a 20% gain in 2021 sours as Ark's flagship fund sees worst return since inception</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood's prediction for a 20% gain in 2021 sours as Ark's flagship fund sees worst return since inception\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 11:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://markets.businessinsider.com/news/etf/ark-invest-worst-return-since-inception-cathie-wood-prediction-flops-2021-12><strong>Businessinsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cathie Wood's expectation for a 20% gain in her Ark Invest flagship fund didn't pan out this year.\nArk Invest's Disruptive Innovation ETF instead has fallen more than 20% in 2021, representing its ...</p>\n\n<a href=\"https://markets.businessinsider.com/news/etf/ark-invest-worst-return-since-inception-cathie-wood-prediction-flops-2021-12\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF"},"source_url":"https://markets.businessinsider.com/news/etf/ark-invest-worst-return-since-inception-cathie-wood-prediction-flops-2021-12","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121988660","content_text":"Cathie Wood's expectation for a 20% gain in her Ark Invest flagship fund didn't pan out this year.\nArk Invest's Disruptive Innovation ETF instead has fallen more than 20% in 2021, representing its worst return since inception.\nWood now expects the growth-oriented ETF to deliver a compounded annual growth rate of up to 40% over the next 5 years.\n\n\nIt's been a difficult year for investors in Ark Invest's flagshipDisruptive Innovation ETF, with the fund on track for its worst year of performance since launching in 2014.\nThat's after the ETF delivered sky-high returns of 150% in 2020, helping Ark Invest amass more than $17 billion in assets under management in its flagship fund. The ETF is down 21% in 2021, while theS&P 500is up about 30% year-to-date.\nArk Invest's poor returns in 2021 were likely a surprise to Cathie Wood, who forecasted a five-year compounded annual growth rateof 20% in December of 2020.She now expects even higher returns looking forward, with a recent blog post outlining her view that the fund could deliver a five-year compounded annual growth rate of up to 40%.\nBut Wood's prediction for a 20% gain in 2021 looked to be correct earlier this year, with the fund up 25% at its peak in February. Since then, a downturn in work-from-home stocks and unprofitable technology names dragged down its performance considerably.\nThe stocks that hit Ark Invest's performance the mostincludeTeladocandZoom Video, which are both down about 50% this year and lowered the fund by 550 and 386 basis points, respectively, according to data fromKoyfin.\nThose losses far outweighed Ark Invest's top performing holding,Tesla, which is up more than 56% year-to-date and boosted the fund by 286 basis points.\nAnd it's not just Ark Invest's flagship ETF that has had a rough year, with five out of Ark's six active ETF's delivering negative returns year-to-date. The Ark Genomic Revolution ETFis the worst performing fund, down about 33% year-to-date, while the Ark Autonomous Technology and Robotics ETF is the best performing fund, up about 3%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879216991,"gmtCreate":1636727972482,"gmtModify":1636727972482,"author":{"id":"3576901678834606","authorId":"3576901678834606","authorIdStr":"3576901678834606","name":"HOOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576901678834606"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879216991","repostId":"2182094779","repostType":4,"repost":{"id":"2182094779","pubTimestamp":1636723680,"share":"https://www.laohu8.com/m/news/2182094779?lang=&edition=full","pubTime":"2021-11-12 21:28","market":"us","language":"en","title":"The Smartest Stocks to Buy With $20 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2182094779","media":"Motley Fool","summary":"A small amount of money can go a long way when invested in these top-notch stocks.","content":"<p>Time and again, Wall Street has shown investors the power of patience.</p>\n<p>Over the past 71 years, the broad-based <b>S&amp;P 500</b> has undergone 38 double-digit percentage corrections. Despite the regularity of these moves lower, every crash and correction throughout this period was eventually erased by a bull market rally. To put things succinctly, if investors buy great companies and allow their investment theses to play out over long periods of time, their chances of building wealth is very high.</p>\n<p>Best of all, with most online brokerages discarding minimum deposit requirements and commission fees, investors can begin or further their trek to financial independence with any amount of cash -- even $20. If you have $20 ready to put to work in the market, and it won't be needed to cover bills or other essential costs, the following trio of companies are the smartest stocks to buy right now.</p>\n<h2>Exelixis</h2>\n<p>One of the savviest stocks patient investors can buy right now with $20 is cancer-drug developer <b>Exelixis</b> (NASDAQ:EXEL).</p>\n<p>Last week, Exelixis announced its third-quarter operating results, which failed to hit the mark and sent its shares down by more than 10%. Sales of lead-drug Cabometyx were shy of Wall Street's expectations, which caused Exelixis to lower the upper end of its full-year sales outlook. Generally, lowering sales expectations will be met with frowns on Wall Street.</p>\n<p>However, this short-term weakness should be viewed as an opportunity, especially with the company's price-to-earnings-growth ratio (PEG ratio) below 0.4. A PEG ratio below 1 is typically considered \"undervalued.\"</p>\n<p>Although the landscape for first-line advanced renal cell carcinoma (RCC) is competitive, Cabometyx has demonstrated the ability to grow sales by a sustained double-digit percentage in RCC and advanced hepatocellular carcinoma. On an annual run-rate basis, Cabometyx is pacing more than $1 billion in sales -- and it's not done growing.</p>\n<p>More importantly, Exelixis' lead drug is being examined in close to six dozen clinical trials as a monotherapy or combination treatment. If even a handful of these trials yield a positive result, label-expansion opportunities and organic growth could send Cabometyx to north of $2 billion in peak annual sales.</p>\n<p>Additionally, Exelixis' robust cash position ($1.8 billion in cash, cash equivalents, and restricted cash) and healthy operating cash flow have allowed it to reignite its internal research engine. This includes advancing internally developed compounds into phase 1 studies, as well as signing collaboration agreements to potentially expand its cancer-drug pipeline.</p>\n<p>It's not often you can marry growth and value with the same company, but that's exactly what investors can do with biotech stock Exelixis.</p>\n<h2>Jushi Holdings</h2>\n<p>Some of the most deeply discounted growth stocks can be found in the marijuana industry, which is why U.S. multi-state operator (MSO) <b>Jushi Holdings</b> (OTC:JUSHF) makes for a smart buy with $20.</p>\n<p>To start with, don't be concerned about a lack of cannabis reform in Washington. While life would undoubtedly be easier for pot stocks if lawmakers would simply follow the overwhelming will of the public and legalize cannabis, allowing individual states to legalize and regulate their pot industries is working fine. Thus far, 36 states have given the green light to weed in some capacity, which is providing growth opportunities for MSOs like Jushi.</p>\n<p>In relative terms, Jushi is a small fry, with only 26 operating dispensaries at the moment. Comparatively, a handful of MSOs have in the neighborhood of (or more than) 100 open locations. But Jushi isn't about reckless expansion. Its management team favors methodical expansion in core markets. For Jushi, these core states are Pennsylvania, Illinois, and Virginia.</p>\n<p>The reason management has chosen these states is due to their billion-dollar sales potential (Illinois hit $1 billion in legal pot revenue in 2020) and their limited-license status. In limited-license cannabis markets, regulators purposely limit how many dispensary licenses are issued in total, as well as to a single business. For a smaller player like Jushi, this competitive protection ensures it'll have a fair shot to build up its brand(s) and garner a loyal following in these core markets.</p>\n<p>Something else impressive about Jushi, and <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the reasons I plan to be a long-term shareholder, is the participation of management and insiders. Of the first $250 million raised by the company, $45 million came from insiders and execs. When leadership has skin in the game right alongside their investors, good things tend to happen.</p>\n<p>Jushi is expected to turn the corner to recurring profitability in 2022 and the company's growing sales faster than virtually all other MSOs. The company checks all the appropriate boxes for growth investors.</p>\n<h2>Viatris</h2>\n<p>On the other hand, if value runs through your blood, generic-drug giant <b>Viatris</b> (NASDAQ:VTRS) is one of the smartest stocks you can buy right now with $20.</p>\n<p>Roughly a year ago, Viatris was born from the combination of <b>Pfizer</b>'s established drug unit Upjohn with generic-drug developer Mylan. Due to generic-drug price weakness throughout the industry, the company's first year as a public company has been one to forget. However, this near-term underperformance represents the perfect opportunity for patient investors to nab an exceptionally inexpensive and profitable drug stock.</p>\n<p>There were a number of reasons Upjohn and Mylan tied the knot. First off, there were clear-cut cost synergies. The company expects to recognize more than $500 million in cost synergies this year, with well over $1 billion in annual cost reductions by 2023.</p>\n<p>As a combined company, Viatris is also in a better position to tackle its outstanding debt. Through the first six months of 2021, $1.15 billion in debt was repaid. By the end of 2023, $6.5 billion in debt should be repaid, which represents a quarter of the company's combined debt ($26 billion), as of November 2020.</p>\n<p>Beyond just trimming the fat, Viatris should be able to kick-start its internal drug research in 2024 once debt levels are reduced to more favorable levels. Keep in mind that new drug research would come atop existing biosimilar clinical trials, which are expected to generate billions of dollars in future sales.</p>\n<p>Viatris won't deliver jaw-dropping growth like Jushi, or even double-digit annual sales upside like Exelixis. But with a steadiness to generic-drug demand and an improving balance sheet, Viatris' forward price-to-earnings ratio below 4 simply doesn't do its stock justice.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Smartest Stocks to Buy With $20 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Smartest Stocks to Buy With $20 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time and again, Wall Street has shown investors the power of patience.\nOver the past 71 years, the broad-based S&P 500 has undergone 38 double-digit percentage corrections. Despite the regularity of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXEL":"伊克力西斯","JUSHF":"Jushi Holdings Inc.","VTRS":"Viatris Inc."},"source_url":"https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2182094779","content_text":"Time and again, Wall Street has shown investors the power of patience.\nOver the past 71 years, the broad-based S&P 500 has undergone 38 double-digit percentage corrections. Despite the regularity of these moves lower, every crash and correction throughout this period was eventually erased by a bull market rally. To put things succinctly, if investors buy great companies and allow their investment theses to play out over long periods of time, their chances of building wealth is very high.\nBest of all, with most online brokerages discarding minimum deposit requirements and commission fees, investors can begin or further their trek to financial independence with any amount of cash -- even $20. If you have $20 ready to put to work in the market, and it won't be needed to cover bills or other essential costs, the following trio of companies are the smartest stocks to buy right now.\nExelixis\nOne of the savviest stocks patient investors can buy right now with $20 is cancer-drug developer Exelixis (NASDAQ:EXEL).\nLast week, Exelixis announced its third-quarter operating results, which failed to hit the mark and sent its shares down by more than 10%. Sales of lead-drug Cabometyx were shy of Wall Street's expectations, which caused Exelixis to lower the upper end of its full-year sales outlook. Generally, lowering sales expectations will be met with frowns on Wall Street.\nHowever, this short-term weakness should be viewed as an opportunity, especially with the company's price-to-earnings-growth ratio (PEG ratio) below 0.4. A PEG ratio below 1 is typically considered \"undervalued.\"\nAlthough the landscape for first-line advanced renal cell carcinoma (RCC) is competitive, Cabometyx has demonstrated the ability to grow sales by a sustained double-digit percentage in RCC and advanced hepatocellular carcinoma. On an annual run-rate basis, Cabometyx is pacing more than $1 billion in sales -- and it's not done growing.\nMore importantly, Exelixis' lead drug is being examined in close to six dozen clinical trials as a monotherapy or combination treatment. If even a handful of these trials yield a positive result, label-expansion opportunities and organic growth could send Cabometyx to north of $2 billion in peak annual sales.\nAdditionally, Exelixis' robust cash position ($1.8 billion in cash, cash equivalents, and restricted cash) and healthy operating cash flow have allowed it to reignite its internal research engine. This includes advancing internally developed compounds into phase 1 studies, as well as signing collaboration agreements to potentially expand its cancer-drug pipeline.\nIt's not often you can marry growth and value with the same company, but that's exactly what investors can do with biotech stock Exelixis.\nJushi Holdings\nSome of the most deeply discounted growth stocks can be found in the marijuana industry, which is why U.S. multi-state operator (MSO) Jushi Holdings (OTC:JUSHF) makes for a smart buy with $20.\nTo start with, don't be concerned about a lack of cannabis reform in Washington. While life would undoubtedly be easier for pot stocks if lawmakers would simply follow the overwhelming will of the public and legalize cannabis, allowing individual states to legalize and regulate their pot industries is working fine. Thus far, 36 states have given the green light to weed in some capacity, which is providing growth opportunities for MSOs like Jushi.\nIn relative terms, Jushi is a small fry, with only 26 operating dispensaries at the moment. Comparatively, a handful of MSOs have in the neighborhood of (or more than) 100 open locations. But Jushi isn't about reckless expansion. Its management team favors methodical expansion in core markets. For Jushi, these core states are Pennsylvania, Illinois, and Virginia.\nThe reason management has chosen these states is due to their billion-dollar sales potential (Illinois hit $1 billion in legal pot revenue in 2020) and their limited-license status. In limited-license cannabis markets, regulators purposely limit how many dispensary licenses are issued in total, as well as to a single business. For a smaller player like Jushi, this competitive protection ensures it'll have a fair shot to build up its brand(s) and garner a loyal following in these core markets.\nSomething else impressive about Jushi, and one of the reasons I plan to be a long-term shareholder, is the participation of management and insiders. Of the first $250 million raised by the company, $45 million came from insiders and execs. When leadership has skin in the game right alongside their investors, good things tend to happen.\nJushi is expected to turn the corner to recurring profitability in 2022 and the company's growing sales faster than virtually all other MSOs. The company checks all the appropriate boxes for growth investors.\nViatris\nOn the other hand, if value runs through your blood, generic-drug giant Viatris (NASDAQ:VTRS) is one of the smartest stocks you can buy right now with $20.\nRoughly a year ago, Viatris was born from the combination of Pfizer's established drug unit Upjohn with generic-drug developer Mylan. Due to generic-drug price weakness throughout the industry, the company's first year as a public company has been one to forget. However, this near-term underperformance represents the perfect opportunity for patient investors to nab an exceptionally inexpensive and profitable drug stock.\nThere were a number of reasons Upjohn and Mylan tied the knot. First off, there were clear-cut cost synergies. The company expects to recognize more than $500 million in cost synergies this year, with well over $1 billion in annual cost reductions by 2023.\nAs a combined company, Viatris is also in a better position to tackle its outstanding debt. Through the first six months of 2021, $1.15 billion in debt was repaid. By the end of 2023, $6.5 billion in debt should be repaid, which represents a quarter of the company's combined debt ($26 billion), as of November 2020.\nBeyond just trimming the fat, Viatris should be able to kick-start its internal drug research in 2024 once debt levels are reduced to more favorable levels. Keep in mind that new drug research would come atop existing biosimilar clinical trials, which are expected to generate billions of dollars in future sales.\nViatris won't deliver jaw-dropping growth like Jushi, or even double-digit annual sales upside like Exelixis. But with a steadiness to generic-drug demand and an improving balance sheet, Viatris' forward price-to-earnings ratio below 4 simply doesn't do its stock justice.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829411480,"gmtCreate":1633532758792,"gmtModify":1633532800155,"author":{"id":"3576901678834606","authorId":"3576901678834606","authorIdStr":"3576901678834606","name":"HOOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576901678834606"},"themes":[],"htmlText":"Good post","listText":"Good post","text":"Good post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829411480","repostId":"1103051417","repostType":4,"repost":{"id":"1103051417","pubTimestamp":1633499678,"share":"https://www.laohu8.com/m/news/1103051417?lang=&edition=full","pubTime":"2021-10-06 13:54","market":"us","language":"en","title":"Palantir selected by U.S. Army for intelligence data fabric, analytics solution","url":"https://stock-news.laohu8.com/highlight/detail?id=1103051417","media":"seekingalpha","summary":"(Update: Oct 6, 2021 at 04:06 a.m. ET)\nThe U.S. Army’s Program Manager for Intelligence Systems and ","content":"<p><i><b>(Update: Oct 6, 2021 at 04:06 a.m. ET)</b></i></p>\n<p>The U.S. Army’s Program Manager for Intelligence Systems and Analytics hasselectedPalantir Technologies(NYSE:PLTR)to deliver the Army's Intelligencedata fabric and analytics foundation for the Capability Drop 2 (CD-2) program.</p>\n<p>The software firm was chosen to advance the next phase of the Army’s competitive $823M indefinite delivery, indefinite quantity (IDIQ) contract.</p>\n<p>It will rollout the Palantir Gotham Platform to support Army Intelligence users worldwide with a globally federated Intelligence data fabric and analytics platform spanning multiple security classifications. The Gotham platform is an operating system for defense decision making.</p>\n<p>This capability will field modern data integration, correlation, fusion, and analytic capabilities that prepare the Army for the next fight against emerging near peer threats. Palantir will also support the Army as they proceed through final testing and fielding.</p>\n<p>Palantir stock rallies over&nbsp;10% in&nbsp;premarket&nbsp;trading&nbsp;Wednesday.<img src=\"https://static.tigerbbs.com/fc8b74ce6066cb21969e52c75982b11a\" tg-width=\"976\" tg-height=\"575\" width=\"100%\" height=\"auto\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir selected by U.S. Army for intelligence data fabric, analytics solution</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir selected by U.S. Army for intelligence data fabric, analytics solution\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-06 13:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3749176-palantir-selected-by-us-army-for-intelligence-data-fabric-analytics-solution><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Oct 6, 2021 at 04:06 a.m. ET)\nThe U.S. Army’s Program Manager for Intelligence Systems and Analytics hasselectedPalantir Technologies(NYSE:PLTR)to deliver the Army's Intelligencedata fabric ...</p>\n\n<a href=\"https://seekingalpha.com/news/3749176-palantir-selected-by-us-army-for-intelligence-data-fabric-analytics-solution\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/news/3749176-palantir-selected-by-us-army-for-intelligence-data-fabric-analytics-solution","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1103051417","content_text":"(Update: Oct 6, 2021 at 04:06 a.m. ET)\nThe U.S. Army’s Program Manager for Intelligence Systems and Analytics hasselectedPalantir Technologies(NYSE:PLTR)to deliver the Army's Intelligencedata fabric and analytics foundation for the Capability Drop 2 (CD-2) program.\nThe software firm was chosen to advance the next phase of the Army’s competitive $823M indefinite delivery, indefinite quantity (IDIQ) contract.\nIt will rollout the Palantir Gotham Platform to support Army Intelligence users worldwide with a globally federated Intelligence data fabric and analytics platform spanning multiple security classifications. The Gotham platform is an operating system for defense decision making.\nThis capability will field modern data integration, correlation, fusion, and analytic capabilities that prepare the Army for the next fight against emerging near peer threats. Palantir will also support the Army as they proceed through final testing and fielding.\nPalantir stock rallies over 10% in premarket trading Wednesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":676,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":838829191,"gmtCreate":1629385935313,"gmtModify":1633685217524,"author":{"id":"3576901678834606","authorId":"3576901678834606","authorIdStr":"3576901678834606","name":"HOOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576901678834606"},"themes":[],"htmlText":"Oh..&nbsp;","listText":"Oh..&nbsp;","text":"Oh..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/838829191","repostId":"1127010631","repostType":4,"repost":{"id":"1127010631","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629380357,"share":"https://www.laohu8.com/m/news/1127010631?lang=&edition=full","pubTime":"2021-08-19 21:39","market":"us","language":"en","title":"Some China concepts stocks tumbled in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1127010631","media":"Tiger Newspress","summary":"(Aug 19) Some China concepts stocks tumbled in morning trading. \nChinese technology stocks sold off,","content":"<p>(Aug 19)&nbsp;Some China concepts stocks tumbled in morning trading.&nbsp;</p>\n<p>Chinese technology stocks sold off, led by some of the country’s Internet giants, after two government ministries said they were likely to impose additional regulations on the sector.</p>\n<p><img src=\"https://static.tigerbbs.com/e4310f534d8b053edff53a4c9e0acd6f\" tg-width=\"275\" tg-height=\"766\" referrerpolicy=\"no-referrer\"></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some China concepts stocks tumbled in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome China concepts stocks tumbled in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-19 21:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Aug 19)&nbsp;Some China concepts stocks tumbled in morning trading.&nbsp;</p>\n<p>Chinese technology stocks sold off, led by some of the country’s Internet giants, after two government ministries said they were likely to impose additional regulations on the sector.</p>\n<p><img src=\"https://static.tigerbbs.com/e4310f534d8b053edff53a4c9e0acd6f\" tg-width=\"275\" tg-height=\"766\" referrerpolicy=\"no-referrer\"></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127010631","content_text":"(Aug 19) Some China concepts stocks tumbled in morning trading. \nChinese technology stocks sold off, led by some of the country’s Internet giants, after two government ministries said they were likely to impose additional regulations on the sector.","news_type":1},"isVote":1,"tweetType":1,"viewCount":90,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":897073561,"gmtCreate":1628865261553,"gmtModify":1633688884628,"author":{"id":"3576901678834606","authorId":"3576901678834606","authorIdStr":"3576901678834606","name":"HOOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576901678834606"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/897073561","repostId":"1145520538","repostType":4,"isVote":1,"tweetType":1,"viewCount":29,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894502525,"gmtCreate":1628835062467,"gmtModify":1633689095863,"author":{"id":"3576901678834606","authorId":"3576901678834606","authorIdStr":"3576901678834606","name":"HOOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576901678834606"},"themes":[],"htmlText":"Great performance&nbsp;","listText":"Great performance&nbsp;","text":"Great performance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/894502525","repostId":"1186962819","repostType":4,"repost":{"id":"1186962819","pubTimestamp":1628809269,"share":"https://www.laohu8.com/m/news/1186962819?lang=&edition=full","pubTime":"2021-08-13 07:01","market":"us","language":"en","title":"Disney jumps over 5% as financials, subscribers top Street expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=1186962819","media":"Seeking Alpha","summary":"Walt Disney is up 5.77% after hours following fiscal third-quarter earnings where it topped expectat","content":"<ul>\n <li><a href=\"https://laohu8.com/S/DIS\">Walt Disney</a> is&nbsp;up 5.77%&nbsp;after hours following&nbsp;fiscal third-quarter earnings&nbsp;where it topped expectations on top and bottom lines and exceeded forecasts for its subscribers to streaming service Disney+.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/143228ff7ee429571324090db7a54eed\" tg-width=\"1039\" tg-height=\"898\" width=\"100%\" height=\"auto\"></p>\n<ul>\n <li>Those subscribers hit 116 million, vs. an expected 112.8 million. Across its streaming services, including Disney+, ESPN+ and Hulu, the company is near 174 million subscribers.</li>\n <li>Revenues grew 45% to $17 billion, and the company swung back to a $995 million profit from last year's $4.84 billion loss.</li>\n <li>Earnings from continuing operations swung to a gain of 50 cents a share from a year-ago loss of $2.61 a share. Adjusted earnings jumped to 80 cents a share from 8 cents a share in the year-ago quarter.</li>\n <li>Revenue by segment: Disney Media and Entertainment Distribution, $12.68 billion (up 18%); Disney Parks, Experiences and Products, $4.34 billion (up 308%).</li>\n <li>The company warned about the ongoing recovery from the COVID-19 pandemic. On the content side: \"Although most film and television production resumed beginning in the fourth quarter of fiscal 2020, we continue to see disruption of film and television production, as well as live sports events, depending on local circumstances. Fewer theatrical releases and production delays have limited the availability of film content to be sold in the subsequent home entertainment and TV/ SVOD distribution windows.\"</li>\n <li>As for the Parks, Experiences and Products segment: \"Although results have improved in the current quarter compared to the prior-year quarter from reopening our parks and resorts, we continue to be impacted by the suspension of cruise ship sailings (with an ongoing return of cruise ship sailings beginning in July 2021) and reduced operating capacities across many of our Disney Parks, Experiences and Products businesses.\"</li>\n <li>Conference call will come at 4:30 p.m. ET.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/ae1db1aa3d9adcf732e52db95921514f\" tg-width=\"885\" tg-height=\"641\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disney jumps over 5% as financials, subscribers top Street expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisney jumps over 5% as financials, subscribers top Street expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-13 07:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3729870-disney-stock-jumps-5-as-financials-subscribers-top-street-expectations><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Walt Disney is up 5.77% after hours following fiscal third-quarter earnings where it topped expectations on top and bottom lines and exceeded forecasts for its subscribers to streaming service Disney...</p>\n\n<a href=\"https://seekingalpha.com/news/3729870-disney-stock-jumps-5-as-financials-subscribers-top-street-expectations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼"},"source_url":"https://seekingalpha.com/news/3729870-disney-stock-jumps-5-as-financials-subscribers-top-street-expectations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186962819","content_text":"Walt Disney is up 5.77% after hours following fiscal third-quarter earnings where it topped expectations on top and bottom lines and exceeded forecasts for its subscribers to streaming service Disney+.\n\n\n\nThose subscribers hit 116 million, vs. an expected 112.8 million. Across its streaming services, including Disney+, ESPN+ and Hulu, the company is near 174 million subscribers.\nRevenues grew 45% to $17 billion, and the company swung back to a $995 million profit from last year's $4.84 billion loss.\nEarnings from continuing operations swung to a gain of 50 cents a share from a year-ago loss of $2.61 a share. Adjusted earnings jumped to 80 cents a share from 8 cents a share in the year-ago quarter.\nRevenue by segment: Disney Media and Entertainment Distribution, $12.68 billion (up 18%); Disney Parks, Experiences and Products, $4.34 billion (up 308%).\nThe company warned about the ongoing recovery from the COVID-19 pandemic. On the content side: \"Although most film and television production resumed beginning in the fourth quarter of fiscal 2020, we continue to see disruption of film and television production, as well as live sports events, depending on local circumstances. Fewer theatrical releases and production delays have limited the availability of film content to be sold in the subsequent home entertainment and TV/ SVOD distribution windows.\"\nAs for the Parks, Experiences and Products segment: \"Although results have improved in the current quarter compared to the prior-year quarter from reopening our parks and resorts, we continue to be impacted by the suspension of cruise ship sailings (with an ongoing return of cruise ship sailings beginning in July 2021) and reduced operating capacities across many of our Disney Parks, Experiences and Products businesses.\"\nConference call will come at 4:30 p.m. ET.","news_type":1},"isVote":1,"tweetType":1,"viewCount":27,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894913539,"gmtCreate":1628781839721,"gmtModify":1633689513395,"author":{"id":"3576901678834606","authorId":"3576901678834606","authorIdStr":"3576901678834606","name":"HOOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576901678834606"},"themes":[],"htmlText":"Overvalue","listText":"Overvalue","text":"Overvalue","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894913539","repostId":"2158325931","repostType":4,"repost":{"id":"2158325931","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628776169,"share":"https://www.laohu8.com/m/news/2158325931?lang=&edition=full","pubTime":"2021-08-12 21:49","market":"us","language":"en","title":"BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster","url":"https://stock-news.laohu8.com/highlight/detail?id=2158325931","media":"Tiger Newspress","summary":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previo","content":"<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-12 21:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158325931","content_text":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.\n\nBioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.\nThe WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.\nThere is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.\nBioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.\nThe conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.\nPfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.","news_type":1},"isVote":1,"tweetType":1,"viewCount":28,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":894502525,"gmtCreate":1628835062467,"gmtModify":1633689095863,"author":{"id":"3576901678834606","authorId":"3576901678834606","authorIdStr":"3576901678834606","name":"HOOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576901678834606"},"themes":[],"htmlText":"Great performance&nbsp;","listText":"Great performance&nbsp;","text":"Great performance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/894502525","repostId":"1186962819","repostType":4,"isVote":1,"tweetType":1,"viewCount":27,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":829411480,"gmtCreate":1633532758792,"gmtModify":1633532800155,"author":{"id":"3576901678834606","authorId":"3576901678834606","authorIdStr":"3576901678834606","name":"HOOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576901678834606"},"themes":[],"htmlText":"Good post","listText":"Good post","text":"Good post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829411480","repostId":"1103051417","repostType":4,"isVote":1,"tweetType":1,"viewCount":676,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879216991,"gmtCreate":1636727972482,"gmtModify":1636727972482,"author":{"id":"3576901678834606","authorId":"3576901678834606","authorIdStr":"3576901678834606","name":"HOOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576901678834606"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879216991","repostId":"2182094779","repostType":4,"isVote":1,"tweetType":1,"viewCount":1105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":838829191,"gmtCreate":1629385935313,"gmtModify":1633685217524,"author":{"id":"3576901678834606","authorId":"3576901678834606","authorIdStr":"3576901678834606","name":"HOOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576901678834606"},"themes":[],"htmlText":"Oh..&nbsp;","listText":"Oh..&nbsp;","text":"Oh..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/838829191","repostId":"1127010631","repostType":4,"isVote":1,"tweetType":1,"viewCount":90,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":897073561,"gmtCreate":1628865261553,"gmtModify":1633688884628,"author":{"id":"3576901678834606","authorId":"3576901678834606","authorIdStr":"3576901678834606","name":"HOOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576901678834606"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/897073561","repostId":"1145520538","repostType":4,"repost":{"id":"1145520538","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628863577,"share":"https://www.laohu8.com/m/news/1145520538?lang=&edition=full","pubTime":"2021-08-13 22:06","market":"us","language":"en","title":"SoFi shares tumbled more than 14% in early trading.","url":"https://stock-news.laohu8.com/highlight/detail?id=1145520538","media":"Tiger Newspress","summary":"SoFi shares tumbled more than 14% in early trading.\nThe company reported a second-quarter net loss o","content":"<p>SoFi&nbsp;shares&nbsp;tumbled&nbsp;more&nbsp;than&nbsp;14%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ba9d52e1cfc7935c2fe253aab7d8907b\" tg-width=\"893\" tg-height=\"598\" referrerpolicy=\"no-referrer\">The company reported a second-quarter net loss of $165.3 million, or 48 cents a share, whereas it recorded net income of $7.8 million a year earlier. Analysts tracked by FactSet were anticipating a 6-cent loss per share.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SoFi shares tumbled more than 14% in early trading.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoFi shares tumbled more than 14% in early trading.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-13 22:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SoFi&nbsp;shares&nbsp;tumbled&nbsp;more&nbsp;than&nbsp;14%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ba9d52e1cfc7935c2fe253aab7d8907b\" tg-width=\"893\" tg-height=\"598\" referrerpolicy=\"no-referrer\">The company reported a second-quarter net loss of $165.3 million, or 48 cents a share, whereas it recorded net income of $7.8 million a year earlier. Analysts tracked by FactSet were anticipating a 6-cent loss per share.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SOFI":"SoFi Technologies Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145520538","content_text":"SoFi shares tumbled more than 14% in early trading.\nThe company reported a second-quarter net loss of $165.3 million, or 48 cents a share, whereas it recorded net income of $7.8 million a year earlier. Analysts tracked by FactSet were anticipating a 6-cent loss per share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":29,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":692097390,"gmtCreate":1640789044505,"gmtModify":1640789044505,"author":{"id":"3576901678834606","authorId":"3576901678834606","authorIdStr":"3576901678834606","name":"HOOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576901678834606"},"themes":[],"htmlText":"Wait","listText":"Wait","text":"Wait","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692097390","repostId":"1121988660","repostType":4,"repost":{"id":"1121988660","pubTimestamp":1640750325,"share":"https://www.laohu8.com/m/news/1121988660?lang=&edition=full","pubTime":"2021-12-29 11:58","market":"us","language":"en","title":"Cathie Wood's prediction for a 20% gain in 2021 sours as Ark's flagship fund sees worst return since inception","url":"https://stock-news.laohu8.com/highlight/detail?id=1121988660","media":"Businessinsider","summary":"Cathie Wood's expectation for a 20% gain in her Ark Invest flagship fund didn't pan out this year.\nA","content":"<ul>\n <li>Cathie Wood's expectation for a 20% gain in her Ark Invest flagship fund didn't pan out this year.</li>\n <li>Ark Invest's Disruptive Innovation ETF instead has fallen more than 20% in 2021, representing its worst return since inception.</li>\n <li>Wood now expects the growth-oriented ETF to deliver a compounded annual growth rate of up to 40% over the next 5 years.</li>\n</ul>\n<hr>\n<p>It's been a difficult year for investors in Ark Invest's flagshipDisruptive Innovation ETF, with the fund on track for its worst year of performance since launching in 2014.</p>\n<p>That's after the ETF delivered sky-high returns of 150% in 2020, helping Ark Invest amass more than $17 billion in assets under management in its flagship fund. The ETF is down 21% in 2021, while theS&amp;P 500is up about 30% year-to-date.</p>\n<p>Ark Invest's poor returns in 2021 were likely a surprise to Cathie Wood, who forecasted a five-year compounded annual growth rateof 20% in December of 2020.She now expects even higher returns looking forward, with a recent blog post outlining her view that the fund could deliver a&nbsp;five-year compounded annual growth rate of up to 40%.</p>\n<p>But Wood's prediction for a 20% gain in 2021 looked to be correct earlier this year, with the fund up 25% at its peak in February. Since then, a downturn in work-from-home stocks and unprofitable technology names dragged down its performance considerably.</p>\n<p>The stocks&nbsp;that hit Ark Invest's performance the mostincludeTeladocandZoom Video, which are both down about 50% this year and lowered the fund by 550 and 386 basis points, respectively, according to data fromKoyfin.</p>\n<p>Those losses far outweighed Ark Invest's top performing holding,Tesla, which is up more than 56% year-to-date and boosted the fund by 286 basis points.</p>\n<p>And it's not just Ark Invest's flagship ETF that has had a rough year, with five out of Ark's six active ETF's delivering negative returns year-to-date. The&nbsp;Ark Genomic Revolution ETFis the worst performing fund, down about 33% year-to-date, while the&nbsp;Ark Autonomous Technology and Robotics ETF&nbsp;is the best performing fund, up about 3%.</p>","source":"lsy1636471102575","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood's prediction for a 20% gain in 2021 sours as Ark's flagship fund sees worst return since inception</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood's prediction for a 20% gain in 2021 sours as Ark's flagship fund sees worst return since inception\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 11:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://markets.businessinsider.com/news/etf/ark-invest-worst-return-since-inception-cathie-wood-prediction-flops-2021-12><strong>Businessinsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cathie Wood's expectation for a 20% gain in her Ark Invest flagship fund didn't pan out this year.\nArk Invest's Disruptive Innovation ETF instead has fallen more than 20% in 2021, representing its ...</p>\n\n<a href=\"https://markets.businessinsider.com/news/etf/ark-invest-worst-return-since-inception-cathie-wood-prediction-flops-2021-12\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF"},"source_url":"https://markets.businessinsider.com/news/etf/ark-invest-worst-return-since-inception-cathie-wood-prediction-flops-2021-12","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121988660","content_text":"Cathie Wood's expectation for a 20% gain in her Ark Invest flagship fund didn't pan out this year.\nArk Invest's Disruptive Innovation ETF instead has fallen more than 20% in 2021, representing its worst return since inception.\nWood now expects the growth-oriented ETF to deliver a compounded annual growth rate of up to 40% over the next 5 years.\n\n\nIt's been a difficult year for investors in Ark Invest's flagshipDisruptive Innovation ETF, with the fund on track for its worst year of performance since launching in 2014.\nThat's after the ETF delivered sky-high returns of 150% in 2020, helping Ark Invest amass more than $17 billion in assets under management in its flagship fund. The ETF is down 21% in 2021, while theS&P 500is up about 30% year-to-date.\nArk Invest's poor returns in 2021 were likely a surprise to Cathie Wood, who forecasted a five-year compounded annual growth rateof 20% in December of 2020.She now expects even higher returns looking forward, with a recent blog post outlining her view that the fund could deliver a five-year compounded annual growth rate of up to 40%.\nBut Wood's prediction for a 20% gain in 2021 looked to be correct earlier this year, with the fund up 25% at its peak in February. Since then, a downturn in work-from-home stocks and unprofitable technology names dragged down its performance considerably.\nThe stocks that hit Ark Invest's performance the mostincludeTeladocandZoom Video, which are both down about 50% this year and lowered the fund by 550 and 386 basis points, respectively, according to data fromKoyfin.\nThose losses far outweighed Ark Invest's top performing holding,Tesla, which is up more than 56% year-to-date and boosted the fund by 286 basis points.\nAnd it's not just Ark Invest's flagship ETF that has had a rough year, with five out of Ark's six active ETF's delivering negative returns year-to-date. The Ark Genomic Revolution ETFis the worst performing fund, down about 33% year-to-date, while the Ark Autonomous Technology and Robotics ETF is the best performing fund, up about 3%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":894913539,"gmtCreate":1628781839721,"gmtModify":1633689513395,"author":{"id":"3576901678834606","authorId":"3576901678834606","authorIdStr":"3576901678834606","name":"HOOI","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576901678834606"},"themes":[],"htmlText":"Overvalue","listText":"Overvalue","text":"Overvalue","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894913539","repostId":"2158325931","repostType":4,"isVote":1,"tweetType":1,"viewCount":28,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}